Biostem Technologies Stock Performance
| BSEM Stock | USD 6.28 0.46 6.82% |
Biostem Technologies holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biostem Technologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Biostem Technologies is expected to be smaller as well. Use Biostem Technologies sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Biostem Technologies.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biostem Technologies are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Biostem Technologies displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 140.7 K | |
| Free Cash Flow | -581.6 K |
Biostem |
Biostem Technologies Relative Risk vs. Return Landscape
If you would invest 465.00 in Biostem Technologies on November 12, 2025 and sell it today you would earn a total of 209.00 from holding Biostem Technologies or generate 44.95% return on investment over 90 days. Biostem Technologies is currently generating 1.091% in daily expected returns and assumes 10.1256% risk (volatility on return distribution) over the 90 days horizon. In different words, 90% of otc stocks are less volatile than Biostem, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biostem Technologies Target Price Odds to finish over Current Price
The tendency of Biostem OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 6.28 | 90 days | 6.28 | about 7.11 |
Based on a normal probability distribution, the odds of Biostem Technologies to move above the current price in 90 days from now is about 7.11 (This Biostem Technologies probability density function shows the probability of Biostem OTC Stock to fall within a particular range of prices over 90 days) .
Biostem Technologies Price Density |
| Price |
Predictive Modules for Biostem Technologies
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biostem Technologies. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biostem Technologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biostem Technologies Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Biostem Technologies is not an exception. The market had few large corrections towards the Biostem Technologies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biostem Technologies, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biostem Technologies within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.19 | |
β | Beta against Dow Jones | 0.64 | |
σ | Overall volatility | 1.09 | |
Ir | Information ratio | 0.11 |
Biostem Technologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biostem Technologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biostem Technologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Biostem Technologies is way too risky over 90 days horizon | |
| Biostem Technologies appears to be risky and price may revert if volatility continues | |
| Biostem Technologies currently holds 1.32 M in liabilities. Biostem Technologies has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostem Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Biostem Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostem Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostem to invest in growth at high rates of return. When we think about Biostem Technologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2.52 M. Net Loss for the year was (2.39 M) with profit before overhead, payroll, taxes, and interest of 163.78 K. | |
| Biostem Technologies currently holds about 1.37 M in cash with (581.57 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. |
Biostem Technologies Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Biostem OTC Stock often depends not only on the future outlook of the current and potential Biostem Technologies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biostem Technologies' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 9.2 M | |
| Short Long Term Debt | 4 M |
Biostem Technologies Fundamentals Growth
Biostem OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Biostem Technologies, and Biostem Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biostem OTC Stock performance.
| Return On Equity | -2.21 | |||
| Return On Asset | -0.6 | |||
| Operating Margin | (18.22) % | |||
| Current Valuation | 37.89 M | |||
| Shares Outstanding | 9.24 M | |||
| Price To Earning | (0.49) X | |||
| Price To Sales | 151.81 X | |||
| Revenue | 2.52 M | |||
| EBITDA | (1.59 M) | |||
| Cash And Equivalents | 1.37 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 1.32 M | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (581.57 K) | |||
| Earnings Per Share | (0.58) X | |||
| Total Asset | 2.67 M | |||
| Retained Earnings | (5.31 M) | |||
| Current Asset | 307 K | |||
| Current Liabilities | 1.86 M | |||
About Biostem Technologies Performance
By examining Biostem Technologies' fundamental ratios, stakeholders can obtain critical insights into Biostem Technologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Biostem Technologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Biostem Technologies is traded on OTC Exchange in the United States.Things to note about Biostem Technologies performance evaluation
Checking the ongoing alerts about Biostem Technologies for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Biostem Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biostem Technologies is way too risky over 90 days horizon | |
| Biostem Technologies appears to be risky and price may revert if volatility continues | |
| Biostem Technologies currently holds 1.32 M in liabilities. Biostem Technologies has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostem Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Biostem Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostem Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostem to invest in growth at high rates of return. When we think about Biostem Technologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2.52 M. Net Loss for the year was (2.39 M) with profit before overhead, payroll, taxes, and interest of 163.78 K. | |
| Biostem Technologies currently holds about 1.37 M in cash with (581.57 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. |
- Analyzing Biostem Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biostem Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Biostem Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biostem Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biostem Technologies' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Biostem Technologies' otc stock. These opinions can provide insight into Biostem Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.